CA2638734A1 - Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation - Google Patents

Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation Download PDF

Info

Publication number
CA2638734A1
CA2638734A1 CA002638734A CA2638734A CA2638734A1 CA 2638734 A1 CA2638734 A1 CA 2638734A1 CA 002638734 A CA002638734 A CA 002638734A CA 2638734 A CA2638734 A CA 2638734A CA 2638734 A1 CA2638734 A1 CA 2638734A1
Authority
CA
Canada
Prior art keywords
hydrogen
pharmaceutical composition
compound
alkyl
xbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002638734A
Other languages
English (en)
Inventor
Albert C. Koong
Douglas E. Feldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Albert C. Koong
Douglas E. Feldman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University, Albert C. Koong, Douglas E. Feldman filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of CA2638734A1 publication Critical patent/CA2638734A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
CA002638734A 2006-02-27 2007-02-27 Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation Abandoned CA2638734A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77745806P 2006-02-27 2006-02-27
US60/777,458 2006-02-27
PCT/US2007/062917 WO2007101224A2 (fr) 2006-02-27 2007-02-27 Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2638734A1 true CA2638734A1 (fr) 2007-09-07

Family

ID=38459802

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002638734A Abandoned CA2638734A1 (fr) 2006-02-27 2007-02-27 Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation
CA002638735A Abandoned CA2638735A1 (fr) 2006-02-27 2007-02-27 Procedes permettant d'identifier les inhibiteurs de reponse aux proteines depliees

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002638735A Abandoned CA2638735A1 (fr) 2006-02-27 2007-02-27 Procedes permettant d'identifier les inhibiteurs de reponse aux proteines depliees

Country Status (5)

Country Link
US (3) US8372861B2 (fr)
EP (1) EP1999303A4 (fr)
AU (2) AU2007220039A1 (fr)
CA (2) CA2638734A1 (fr)
WO (2) WO2007101225A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101225A2 (fr) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Procedes permettant d'identifier les inhibiteurs de reponse aux proteines depliees
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
EP2391372A4 (fr) * 2009-01-30 2013-07-03 Bayer Healthcare Llc Méthodes de traitement de cancer positif aux récepteurs oestrogéniques par inhibition de la protéine de liaison à la boîte x 1 (xbp1)
CA3042107C (fr) 2009-11-03 2023-03-07 Fosun Orinove Pharmatech, Inc. Inhibiteurs de l'ire-1.alpha.
US20120028933A1 (en) 2010-07-28 2012-02-02 Baust John M Cell Culture Media Supplement and Method of Molecular Stress Control
US8993617B2 (en) 2010-11-10 2015-03-31 The Board Of Trustees Of The Leland Stanford Junior University Ire1alpha endonuclease specific inhibitor with cytotoxic activity
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
EP2694059A4 (fr) 2011-04-04 2014-10-15 Univ Georgetown Inhibiteurs à petites molécules de l'épissage de xbp1
EP2696859A1 (fr) * 2011-04-13 2014-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de criblage et compositions pharmaceutiques pour le traitement de syndromes abdominaux inflammatoires
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
US9296994B2 (en) 2012-04-23 2016-03-29 Imba-Institut Für Molekulare Biotechnologie Gmbh Archease as RNA ligaes complex member
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
CN105491883B (zh) 2013-06-13 2018-11-02 生物马特里卡公司 细胞稳定化
DK3049521T3 (en) 2013-09-25 2019-04-23 Univ Cornell Compounds for inducing antitumor immunity and methods thereof
US9447054B2 (en) * 2014-01-15 2016-09-20 Korea Institute Of Radiological & Medical Sciences Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient
KR101643281B1 (ko) * 2014-01-15 2016-08-11 한국원자력의학원 벤조[ｄ]옥사졸 유도체를 유효성분으로 함유하는 항암활성 보조제
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
WO2015178770A1 (fr) * 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
HUE042335T2 (hu) 2014-10-14 2019-06-28 Vitae Pharmaceuticals Inc ROR-gamma dihidropirrolopiridin inhibitorai
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016081599A1 (fr) * 2014-11-18 2016-05-26 Rutgers, The State University Of New Jersey Nouveaux découplants mitochondriaux pour le traitement de maladies métaboliques et du cancer
EP3331876B1 (fr) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulateurs de ror-gamma
EP3377482B1 (fr) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulateurs de ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CA3024610A1 (fr) 2016-05-18 2017-11-23 David J. Augeri Nouveaux decouplants mitochondriaux pour le traitement de maladies metaboliques et du cancer
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2018102552A1 (fr) 2016-11-30 2018-06-07 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
JP7126084B2 (ja) 2017-06-01 2022-08-26 コーネル ユニバーシティー Ｉｒｅ１小分子阻害薬
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma
US11525165B2 (en) 2017-12-20 2022-12-13 Inserm Method of selection of an IRE1-inhibitor therapy for patient suffering from cancer
EP3802514B1 (fr) * 2018-06-01 2022-08-03 Promega Corporation Inhibiteurs de complexes bioluminescents dérivés de la luciférase oplophorus
CN109574920B (zh) * 2018-12-25 2022-03-04 药大制药有限公司 3-腈基-6环丙基吡啶类ido1抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
JP2000506007A (ja) * 1996-02-23 2000-05-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 細胞によるアッセイ
US5958703A (en) * 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
JP2002501892A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US20030049701A1 (en) * 2000-09-29 2003-03-13 Muraca Patrick J. Oncology tissue microarrays
US7666587B2 (en) * 2002-04-12 2010-02-23 New York University Method of screening test substances for treating or preventing a disease mediated by plasma cells
EP1572944A4 (fr) * 2002-08-30 2007-12-26 Harvard College Procedes et compositions permettant la modulation de l'activite xbp-1
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
US20060247320A1 (en) * 2005-03-09 2006-11-02 Schering Corporation Compounds for inhibiting KSP kinesin activity
WO2007101225A2 (fr) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Procedes permettant d'identifier les inhibiteurs de reponse aux proteines depliees

Also Published As

Publication number Publication date
US20090291857A1 (en) 2009-11-26
WO2007101224A2 (fr) 2007-09-07
AU2007220039A1 (en) 2007-09-07
WO2007101224A3 (fr) 2008-10-16
WO2007101225A2 (fr) 2007-09-07
AU2007220040A1 (en) 2007-09-07
US8372861B2 (en) 2013-02-12
EP1999303A4 (fr) 2010-09-08
EP1999303A2 (fr) 2008-12-10
US20090312362A1 (en) 2009-12-17
WO2007101225A3 (fr) 2009-04-02
CA2638735A1 (fr) 2007-09-07
US20130150399A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
US8372861B2 (en) Inhibitors of the unfolded protein response and methods for their use
EP3184519B1 (fr) Sel d'addition acide de composé inhibiteur de trk
EP1626714B1 (fr) Urees de diaryle pour des maladies mediees par le recepteur du facteur de croissance derive des plaquettes
CN101222850B (zh) 治疗对药物有抗性的癌症的方法
JPH11507052A (ja) キナゾリンおよび医薬組成物
EA013209B1 (ru) Производные дифенилоксиндол-2-она и их применение для лечения рака
US20220144845A1 (en) SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS
US10464939B2 (en) Deuterated triazolopyridazine as a kinase modulator
MX2014015938A (es) Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cancer, inflamacion autoinmune y trastornos del sistema nervioso central.
EA039630B1 (ru) N-замещенные индольные производные
JP2022174272A (ja) クロモボックスタンパク質阻害剤およびその使用
JP2018514557A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
JP2019504879A (ja) ベンゾチアゾール両親媒性物質
WO2015004212A1 (fr) Inhibiteur de neuropiline et son utilisation pour le traitement de maladies associées à la neuropiline
WO2010075372A9 (fr) Inhibiteurs de mer11, rad50 et/ou nbs1
JP2008517065A (ja) Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法
Dou et al. Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: computational simulation, biological evaluation and cancer combinational chemotherapy study
AU2015101613A4 (en) Identification of natural small-molecules AMPK activators for treatment of cancers or multidrug-resistant cancers
Moskaleva et al. Molecular mechanisms of antitumor activity of niclosamide
US9611276B2 (en) Imidazo bicyclic iminium compounds as antitumor agents
EP4015516A1 (fr) Dérivé de n-acylhydrazone à base de benzofurane et composition pharmaceutique le comprenant
WO2015123392A1 (fr) Compositions et procédés d'inhibition de l'angiogenèse et la lymphangiogenèse

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20121219

FZDE Discontinued

Effective date: 20150227